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ABSTRACT:  
Patients with chronic kidney disease (CKD) have accelerated bone loss, vascular calcification 
and abnormal biochemistries, together contributing to an increased risk of cardiovascular disease 
and fracture-associated mortality. Despite evidence of vascular pathologies and dysfunction in 
CKD, our group has shown that cortical bone tissue perfusion is higher in a rat model of high-
turnover CKD. The goal of the present study was to test the hypothesis that parathyroid hormone 
(PTH) suppressive interventions would normalize cortical bone vascular perfusion in the setting 
of CKD. In two separate experiments, 35-week old CKD animals and their normal littermates, 
underwent intra-cardiac fluorescent microsphere injection to assess the effect of 10 weeks of PTH 
suppression (Experiment 1: calcium supplementation, Experiment 2: calcimimetic treatment) on 
alterations in bone tissue perfusion. In Experiment 1, CKD animals had serum blood urea nitrogen 
(BUN) and PTH levels significantly higher than NL (+182% and +958%; p<0.05). CKD+Ca 
animals had BUN levels that were similar to CKD, while PTH levels were significantly lower and 
comparable to NL. Both femoral cortex (+220%, p=0.003) and tibial cortex (+336, p=0.005) tissue 
perfusion were significantly higher in CKD animals when compared to NL; perfusion was 
normalized to those of NL in CKD+Ca animals. MicroCT analysis of the proximal tibia cortical 
porosity showed a trend toward higher values in CKD (+401%; p=0.017) but not CKD+Ca (+111%; 
p = 0.38) compared to NL. Experiment 2, using an alternative method of PTH suppression, 
showed similar results as those of Experiment 1. These data demonstrate that PTH-suppression 
based interventions normalize cortical bone perfusion in the setting of CKD.  
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INTRODUCTION 
 Chronic kidney disease–mineral and bone disorder (CKD‐MBD), consisting of  
accelerated bone loss, vascular calcification, and abnormal biochemistries [1], contributes to an 
increased risk of premature death due to cardiovascular disease and fracture-associated mortality 
[2]. Understanding the underlying mechanisms of cardiovascular and skeletal alterations due to 
the sequelae of reduced kidney function, including mechanisms that overlap between 
cardiovascular and skeletal alterations, is crucial to developing novel ways to reduce mortality in 
CKD patients.  
 Patients with CKD have vascular dysfunction through endothelium-dependent, 
endothelium-independent, and/or vascular remodeling mechanisms[3], along with decreased 
cardiac output [4], and vascular calcification [5], suggesting that altered skeletal perfusion can be 
expected in CKD. Bone health and homeostasis are dependent on regulated skeletal perfusion 
[6] and conditions that result in altered bone perfusion have been shown to be associated with 
bone loss [7]. Data from our lab have shown that cortical bone perfusion is elevated in a rat model 
of chronically high parathyroid hormone (PTH), high remodeling CKD [8]. However, whether 
vascular dysfunction and the bone abnormalities are related in CKD is not known.  
 Sustained elevation of serum PTH in the setting of CKD has been shown, by our group 
and others, to contribute to compromised bone quantity and quality via elevated bone turnover 
and increased cortical porosity[9]. Currently, the primary goal of CKD-MBD therapy is the 
suppression of elevated levels of PTH [10] utilizing calcitriol (and its analogues) and 
calcimimetics. Our group has previously shown that the suppression of PTH levels with calcium 
supplementation in drinking water in rodents substantially mitigates the deleterious effects of CKD 
on bone parameters, essentially normalizing bone turnover and mass [11]. Calcimimetics, such 
as the recently FDA-approved etelcalcitide, suppress PTH without contributing to the increased 
vascular calcification [12] observed with calcium supplementation in rodents [11]. For this reason, 
the present study utilizes both calcium supplementation and a calcimimetic to evaluate the effect 
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of PTH suppression therapies on cortical bone perfusion.  We hypothesized these interventions 
would normalize CKD-induced elevations in cortical bone perfusion.  
 
METHODS 
Animals. Male Cy/+ (CKD) rats, Han:SPRD rats are characterized with a spontaneous and slowly 
progressive kidney disease [13]. Blood urea nitrogen (BUN) and creatinine are elevated by 10 
weeks of age. With progression of CKD, hyperphospatemia, hyperparathyroidism, and skeletal 
abnormalities develop and ultimately progress to dramatic manifestations of cardiac and vascular 
calcification as well as severe cortical porosity and compromised bone mechanical properties 
[13]. 
 
Experimental Design.  
Experiment 1:  
CKD animals (n=12) and their normal littermates (NL, n=6) were used to assess alterations in 
skeletal perfusion at 35 weeks of age (~15% normal kidney function in the Cy/+ model). The 
CKD treatment animals were divided into two groups (n=6/group) at 25 weeks of age: half were 
administered normal deionized drinking water (CKD) and the other half administered calcium 
gluconate (3% Ca) in the drinking water (CKD+Ca). The calcium gluconate was used as a 
phosphate binder with the goal of PTH suppression as shown previously [9]. Age‐matched 
normal (NL) littermate animals (n=6) were used as a comparator group to determine if treatment 
normalized skeletal perfusion. All animals were fed a casein diet (Purina AIN‐76A, Purina 
Animal Nutrition, Shreevport, LA, USA); 0.53% Ca and 0.56% P) during the experimental period 
(weeks 25-35), which has been shown to produce a more consistent kidney disease in this 
model [13]. At 35 weeks, all animals were assessed for serum biochemistries approximately 24 
hours before undergoing in vivo microsphere injection to assess bone tissue perfusion. Tibiae, 
femora, and testes were collected for analyses.  
-Page 5 - 
Experiment 2:  
In order to differentiate the effects of PTH lowering from that of increased calcium intake, CKD 
animals (n=6) and their normal littermates (n=4) were used to assess the effect of KP-2326 
(KP), an active metabolite of the calcimimetic etalcalcitide, on CKD-induced alterations in 
skeletal perfusion. The CKD treatment groups (n=3/group) were administered either vehicle 
injections thrice weekly or KP injection thrice weekly (i.p. 1mg/kg) from age 25 to 35 weeks. At 
35 weeks, all animals were assessed for serum biochemistries approximately 24 hours before 
undergoing in vivo microsphere injection to assess bone tissue perfusion. Tibiae were collected 
for analysis.  
 
Plasma Biochemistries. Blood plasma was analyzed for blood urea nitrogen (BUN), calcium, 
phosphorus, and creatinine using colorimetric assays (Point Scientific, Canton, MI, USA; or Sigma 
kits; Sigma, St. Louis, MO, USA). Intact PTH was determined by ELISA (Alpco, Salem, NH, USA).  
 
Bone perfusion measurement. Microsphere injection was performed as we previously 
described [14]. Briefly, under isoflurane anesthesia, polystyrene red fluorescent (580/605), 15 µm 
microspheres (FluoSpheres, ThermoFisher) were injected into the apex of the beating left 
ventricle. The animal was euthanized by cardiac dissection 60 seconds after the completion of 
the injection, allowing for the circulation of spheres. A total of 5.0x106 spheres/kg were injected, 
a number sufficient to assess perfusion in skeletal tissue [14].  
  Tibiae, femora, and testes were collected and weighed. Femoral diaphyses were isolated, 
thoroughly flushed of marrow, and weighed. Marrow was extracted from the tibial diaphysis by 
centrifugation; both marrow and tibial cortex were weighed. In Experiment 2, only the tibia was 
collected for perfusion analysis. The tibial cortex was isolated and marrow was separated by 
centrifugation.  
 Samples isolated for tissue perfusion measures were processed as previously described 
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[14]. Briefly, bone samples were placed in a Cal-Ex Decalcifier solution for 7 days. Decalcified 
bone samples were degraded in 10% ethanolic potassium hydroxide (KOH) for 24 hours. Soft 
tissue samples (testes) were placed in KOH directly. Degraded samples were filtered through 
polyamide mesh filters (5 µm pore size) and placed into microcentrifuge vials along with 1mL of 
Cellosolve acetate (2-ethoxyethyl acetate, 98%, Sigma) to dissolve the microspheres and 
distribute the fluorescence into solution.  
 Fluorescence measurements were performed as previously described [14]. Briefly, three 
100µL aliquots from each sample were placed in a 96-well V-bottom polypropylene microplate for 
fluorescence quantification using the SpectraMax i3x microplate reader (Molecular Devices, CA). 
The readings from the three aliquots were averaged to produce a single fluorescence 
measurement per sample. Red fluorescence was measured using an excitation of 580nm and an 
emission of 620nm. All data is presented as tissue fluorescence density (TFD) with units of 
Arbitrary Units per gram of tissue (AU/g) and scaled by 106.   
 
μCT Imaging. Tibiae were scanned (Skyscan 1172, 6 micron resolution) to obtain cortical 
morphology at a standardized location (~2.5mm distal to the proximal growth plate). Cortical 
parameters included total cross-sectional area, bone area, marrow area, cortical thickness, and 
cortical porosity. Porosity was calculated as the percent of void area within the total cross 
sectional area (100 – BA/TA*100). Nomenclature is reported in accordance with ASBMR 
guidelines [15]. 
 
Statistics. All analyses were performed using GraphPad Prism software. Comparisons among 
groups were assessed by Kruskal-Wallis analysis of ranks with Dunn’s multiple comparisons post-
hoc tests when appropriate. A priori α-levels were set at p < 0.05 to determine statistical 
significance.  
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RESULTS 
Plasma Biochemistries.  
Experiment 1: 
Animals with CKD had serum blood urea nitrogen (BUN) and PTH levels that were significantly 
higher than NL (+182% and +958%; p<0.05) (Table 1). CKD+Ca animals had BUN levels that 
were not different from CKD (p=0.7922), while PTH levels were significantly lower than CKD alone 
(p=0.004) and not different from NL (Table 1). 
Experiment 2: 
Animals with CKD had elevated serum blood urea nitrogen (BUN) and PTH levels compared to 
NL (+119% and +2700%), although due to variability and low sample size, the results did not 
reach statistical significance (Table 1). CKD+KP animals had BUN levels that were not different 
from CKD, while PTH levels were lower than CKD alone and not different from NL (Table 1). 
 
Bone geometry. 
Experiment 1: 
Cortical mean cross-sectional area (p=0.002) was significantly lower in CKD animals when 
compared to NL animals, while the calcium supplementation (CKD+Ca) group was not different 
from NL (Table 2). MicroCT analysis of the proximal tibia cortical porosity was higher in CKD 
(+401% vs. NL; p=0.017) and not different in CKD+Ca (+111% relative to NL; p = 0.38) (Table 
2).   
Experiment 2: 
MicroCT analysis of the proximal tibia demonstrated cortical porosity was significantly higher in 
CKD (+925%; p=0.05) vs. NL, but not different in CKD+KP (+42%; p = 0.86) animals relative to 
NL. Cortical mean cross-sectional area (ANOVA, p=0.09) showed a trend toward lower values in 
CKD (-20%; p=0.078) compared to NL while CKD+KP (-8%; p = 0.70) animals were not different 
compared to NL (Table 2). 
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Bone perfusion measurement.  
Experiment 1: 
Femoral cortex (p=0.003) and tibial cortex (p=0.005) tissue perfusion were both significantly 
higher in CKD animals when compared to NL animals (Figure 1A&B). Calcium supplementation 
resulted in femoral and tibial cortical perfusion that was not different than normal. Isolated marrow 
perfusion (p=0.005) was significantly lower in CKD animals when compared to NL animals 
(Figure 1C). Calcium supplementation resulted in isolated marrow perfusion with values not 
different from CKD animals receiving no treatment.  
Experiment 2: 
Tibial cortex (p=0.05) tissue perfusion was significantly higher in CKD animals when compared 
to NL animals (Figure 1D). KP treatment resulted in tibial cortical perfusion that was not different 
than normal.  Isolated marrow perfusion showed a trend toward lower values in CKD (-63%; 
p=0.11) vs. NL, while CKD+KP were not different from NL (-26%; p = 0.40) (Figure 1E). 
 
DISCUSSION 
CKD causes progressive damage to bone. Bone deterioration in CKD can be characterized by 
changes in turnover, mineralization, and volume [1], where, most commonly, high turnover drives 
bone loss. Altered bone turnover/remodeling has been associated with changes in bone perfusion 
in a number of conditions including diabetes, disuse, aging, and estrogen withdrawal [16] }. In 
turn, reduced bone perfusion has also been associated with bone loss in a number of conditions 
[7]. Since CKD is known to be associated with both cardiac and vascular abnormalities, we 
investigated skeletal perfusion in the setting of CKD to provide insights into the pathophysiology 
of skeletal changes in CKD.  
Previous studies, by our group and others, have shown that sustained elevation of serum 
PTH in the setting of CKD contributes to compromised bone quantity and quality [9].  In the 
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present study, with the use of fluorescent microspheres to measure regional perfusion in bone, 
we show that two methods of PTH suppression normalize CKD-induced elevations in cortical 
bone perfusion. CKD animals with calcium supplementation and calcimimetic treatment had PTH 
levels that were suppressed by 98% and 94% relative to untreated CKD animals, respectively, 
yielding PTH levels that were not significantly different than normal animals. Our group has 
previously shown that the suppression of PTH levels with calcium supplementation in drinking 
water has substantial positive skeletal effects, essentially normalizing bone turnover and volume 
[11]. In the present study, calcium supplementation and calcimimetic treatment resulted in higher 
cortical bone area along with normalized cortical bone perfusion (Figure 2A-B). The normalization 
of cortical bone perfusion via two methods of PTH suppression suggests that perfusion elevations 
are either dependent on PTH, or dependent on a factor secondary to elevated PTH, such as 
increased cell metabolism. PTH suppression can reduce the direct effects of PTH on the 
endothelial expression of vascular endothelial growth factor [17] and consequently normalize 
CKD-induced elevation in cortical bone perfusion. On the other hand, PTH suppression can result 
in the attenuation of the increased metabolic demands [18] of high turnover CKD secondary to 
elevated PTH levels.  
The current study demonstrates lower marrow perfusion in the setting of high PTH/high 
remodeling CKD in two separate experiments that is not completely normalized with either 
calcium supplementation or calcimimetic therapy (Figure 2C). The lack of normalization of CKD-
induced lowering of marrow perfusion in the low PTH/low remodeling CKD state suggests that 
marrow perfusion is not dependent on the high remodeling state in the setting of CKD. Other 
factors including arterial perfusion pressures, myogenic, endothelial, neural and hormonal 
disturbances may explain alterations of marrow perfusion in the setting of CKD. The potential role 
of medullary hypoxia on increased bone resorption via differentiation of osteoclasts requires 
further investigation. 
 Our results should be interpreted in the context of various assumptions and limitations. 
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One limitation of the study is that only male rats were utilized in this study. Female Cy/+ animals 
do not develop notable changes in cortical bone properties and thus were not studied in the 
current context. Injection of microspheres in the left ventricle to assess perfusion is based on a 
set of assumptions and has multiple limitations as discussed in our previous work [14]. While 
these limitations are important to consider from a technical standpoint, we have now consistently 
shown in several studies that in CKD in the setting of high PTH there is higher cortical perfusion. 
Another limitation of our current work is the low number of animals in Experiment 2 which resulted 
in the lack of a significant difference in NL vs.CKD PTH levels in Experiment 2. Despite this 
limitation, the results of calcimimetic treatment paralleled those observed with calcium-induced 
suppression of PTH in that both treatments normalize cortical bone perfusion, without effect on 
marrow perfusion (Figure 2A-C), thus suggesting that the effects may be due to PTH suppression 
rather than the calcium treatment. Further work will be needed to confirm the effect of PTH 
suppression on cortical bone and marrow perfusion.  
The effect of CKD-induced perfusion elevations in cortical bone are normalized by 
interventions aimed at suppression of PTH. The normalization of cortical bone perfusion via two 
methods of PTH suppression suggests that perfusion elevations are may be PTH dependent, 
either directly, or indirectly mediated via another factor.  Determining the mechanisms of these 
bone perfusion alterations and whether they are drivers, propagators, or consequences of skeletal 
deterioration in CKD will necessitate further work but will help untangle a key player in CKD-
induced bone quality alterations. 
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FIGURES 
Figure 1: Bone perfusion data. Experiment 1: Tissue fluorescence density (TFD) of (A) femoral 
cortical bone (Kruskal-Willis, p=0.0030) (B) tibial cortical bone (Kruskal-Willis, p=0.0051) (C) tibial 
bone marrow (Kruskal-Willis, p=0.0047). Experiment 2: Tissue fluorescence density (TFD) of (A) 
tibial cortical bone (Kruskal-Willis, p=0.0505) (B) tibial bone marrow (Kruskal-Willis, p=0.0780). 
Dots represent data points, and error bars represent standard deviation. *p<0.05, different from 
all other groups 
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Figure 2: Combined graphs with data from Experiments 1 & 2: (A) tibial cortical perfusion, (B) 
tibial cortical porosity, (C) tibial marrow perfusion   
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TABLES 
Table 1: Serum biochemistries at end point (35 weeks) 
Experiment 1 
 Normal CKD CKD+Ca 
BUN (mg/dL) 17.8  1.9* 50.4  8.0 49.1  9.4 
PTH (mg/dL) 123  49 2105  139* 33  42 
Experiment 2 
 Normal CKD CKD+KP 
BUN (mg/dL) 20.8  1.8 45.7  2.6 51.2  8.7 
PTH (mg/dL) 263  66 6840  6935 403  265 
Data presented as mean and standard deviation.  *p<0.05, different from all other groups 
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Table 2: Proximal tibia cortical geometry  
Experiment 1 
 Normal CKD CKD+Ca 
Cortical Area (mm2) 7.3  0.2 6.1  0.7* 7.1  0.3 
Cortical Porosity (%) 1.1  2.0 5.7  4.7 2.4  2.3 
Experiment 2 
 Normal CKD CKD+KP 
Cortical Area (mm2) 6.0  0.3 4.8  1.1 5.5  0.1 
Cortical Porosity (%) 2.8  0.5 28.3  22.25* 3.9  2.2 
Data presented as mean and standard deviation.  *p<0.05, compared to Normal group 
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